|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
The ASO also reduced expression of genes involved in matrix expansion such as fibronectin and collagen (I and IV) and an inhibitor of matrix degradation, PAI-1, in the renal cortex, contributing to significant reversal of mesangial expansion in both models of DN.
|
17554073 |
2007 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The plasminogen activator inhibitor-1 (PAI-1) 4G/4G genotype influences the development of diabetic nephropathy and lupus nephritis.
|
15481848 |
2004 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We have examined the association of four candidate genes, angiotensin converting enzyme (ACE): insertion/deletion (I/D) polymorphism, plasminogen activator inhibitor-1 (PAI-1): 4G/5G polymorphism, decorin: 179/183/185 polymorphism and Werner syndrome helicase: C/R polymorphism, with the presence of diabetic nephropathy in Type 1 diabetic patients.
|
10495473 |
1999 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
|
26616527 |
2016 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A meta-analysis was conducted to investigate the association between 4 G/5 G variants in the PAI-1 gene and DN susceptibility.
|
24345290 |
2014 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models.
|
24223897 |
2013 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using multivariate logistic regression analyses, we investigated the independent or synergistic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on the development of diabetic nephropathy and macroangiopathy in 208 patients with non-insulin dependent diabetes mellitus (NIDDM) over a 15 year period.
|
9844142 |
1998 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings provide support that PAI-1 contributes to the development of inflammation in perirenal fat and correlates with the development of diabetic nephropathy in HFD-induced obesity.
|
30532990 |
2019 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
These genes included (a) known regulators of mesangial cell activation in diabetic nephropathy (fibronectin, caldesmon, thrombospondin, and plasminogen activator inhibitor-1), (b) novel genes, and (c) known genes whose induction by high glucose has not been reported.
|
10026205 |
1999 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, PAI-1R provides an additional therapeutic effect in slowing the progression of diabetic nephropathy via the protection of podocytes.
|
24443353 |
2014 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ThePAI1 gene is therefore an excellent candidate gene for diabetic nephropathy.
|
17263760 |
2007 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Protein and mRNA expression of TGF-beta isoforms, TGF-beta 1, -beta 2 and -beta 3, and deposition of fibronectin containing extra domain A (fibronectin EDA+) and plasminogen activator inhibitor-1 (PAI-1) were studied in human chronic glomerulonephritis and diabetic nephropathy.
|
8821830 |
1996 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus progression of diabetic nephropathy may be promoted by PAI-1 upregulation mediated by the glycated albumin-induced Smad/DNA interactions.
|
15198928 |
2004 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Neither the PAI-1 nor the ApoE gene polymorphism contributes to the genetic susceptibility to diabetic nephropathy or retinopathy.
|
10809802 |
2000 |
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Diabetic patients with coexistence of PAI-1 4G/4G genotype and ACE D alleles had a higher incidence of diabetic nephropathy (22 vs. 7%, P = 0.012) than those with other combinations of genotypes.
|
10652041 |
2000 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Stroke prevalence and odds ratio (OR) were assessed for the following parameters: G20210A prothrombin, Arg506Glu factor V Leiden, C677T MTHFR, and 4G/5G PAI-1 polymorphisms; total number of study polymorphisms in a particular subject (genetic sum); and classic vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertriglyceridemia, and elevated levels of low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol.
|
24189452 |
2014 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
|
15194475 |
2004 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Addition of waist circumference to the models either decreased or nullified the contribution of PAI-1act to BP and hypertension development.
|
31356402 |
2019 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism.
|
26934364 |
2017 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Multivariate logistic regression analysis showed that PAI-1 4G/4G (P = 0.01) and the prevalence of hypertension (P < 0.0001) are independent risk factors of development of type 2 diabetic nephropathy.
|
10652041 |
2000 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
When stratified according to PAI-1 4G/5G polymorphism, there was no significant difference in all metabolic parameters among PAI-1 genotype groups in patients with HTN as well as subjects with normal blood pressure.
|
22613596 |
2012 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Patients with metabolic syndrome were characterized with increased body mass index (BMI), waist circumference, and HOMA-IR and HOMA-beta levels, and all had increased blood pressure and triglyceride levels, low high-density lipoprotein cholesterol levels, increased PAI-1 levels and reduced antioxidative defense levels.
|
17848118 |
2007 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The most significant result among all univariate and multivariate tests performed in this study was the heterogeneity of correlation between PAI-1 and mean arterial pressure at rs10738554, near SLC24A2, a gene previously associated with high blood pressure in African Americans.
|
28408189 |
2017 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The present study showed that the 4G/4G genotype was associated with elevated plasma PAI-1 activity in Chinese patients with and without hypertension.
|
12670745 |
2003 |